Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-III invasive breast cancer~* Awaiting surgery or neoadjuvant treatment~* ECOG performance status 0, 1 or 2~* Adequate organ function~* Prior use of hormone contraception or replacement therapy must have been discontinued at least 30 days prior to diagnostic biopsy (unless participant is willing to undergo an additional biopsy for the study)~Exclusion Criteria:~* Prior or current treatment of any kind for the current breast cancer~* Current use of any other investigational drugs~* Uncontrolled or active infection, congestive heart failure, cardiac arrythmia, or psychiatric illness

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat and Tamoxifen (Type: EXPERIMENTAL): Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).